EUVIMEDEUVIMED entdecken
Open Access

Discontinuation of treatment for alcohol use disorder during pregnancy and postpartum in the United States

Absetzen der Behandlung bei Alkoholgebrauchsstörung während Schwangerschaft und Postpartum in den USA

Caitlin E Martin iD, Jennifer K Bello, Bridget M Galati, Joanna L Buss, Mishka Terplan, Hendrée E Jones, Kathleen T Mitchell, Silvia S Martins, Richard A Grucza, Elizabeth A Suarez, Kevin Y Xu iD

Alcohol, Clinical and Experimental Research · 2025-09 · 49 (9) · 1972-1982

DOI: 10.1111/acer.70117 ↗

Auf einen Blick

Bei Schwangeren mit AUD war die Nutzung von MAUD niedrig und brach in der Schwangerschaft deutlich ein. Auch postpartal wurde MAUD nur selten wieder aufgenommen.

Fragestellung

Wie häufig werden MAUD und psychosoziale Interventionen bei Personen mit AUD vor der Schwangerschaft, in der Schwangerschaft und postpartal genutzt, und wie unterscheiden sich schwangere von nicht schwangeren Personen?

Methode

Analyse von MarketScan-Ansprüchen 2016–2019; Vergleich von schwangeren Personen mit AUD und nach Alter, Versicherungstyp und Kalenderzeit gematchten nicht schwangeren Peers; Cox-Regression zur Behandlungsbeendigung.

Ergebnisse

2080 schwangere Personen mit AUD und 7564 gematchte nicht schwangere Peers. MAUD sank in der Schwangerschaft von 12,1 % auf 0,3 %; in der Vergleichsgruppe von 13,5 % auf 8,1 % (p < 0,001). HR für MAUD-Abbruch 2,11 (95 %-KI 1,71–2,60).

Schlussfolgerung der Autor:innen

Unter schwangeren Personen mit präkonzeptionell behandelter AUD ist die MAUD-Nutzung niedrig und das Absetzen häufig; dies hält postpartal an.

Kernaussagen

  • MAUD-Nutzung sank bei Schwangeren von 12,1 % auf 0,3 %
  • Postpartale Wiederaufnahme von MAUD selten: 1,9 % vs. 7,8 %
  • Schwangere brachen MAUD häufiger ab: HR 2,11 (95 %-KI 1,71–2,60)

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Alcohol, Clinical and Experimental Research, online erschienen am 23.08.2025. Verfasst von Caitlin E Martin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology and the VCU Institute for Drug and Alcohol Studies, Virginia Commonwealth University School of Medicine, Rich…. Hauptthemen laut MEDLINE: Postpartum Period, Alcoholism, Pregnancy Complications, Withholding Treatment. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NIH HHS, Saint Louis University.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The degree of alcohol use disorder (AUD) treatment utilization during the perinatal period is unknown. We report the prevalence of preconception receipt of medications for AUD (MAUD) and psychosocial interventions (PSY), discontinuation during pregnancy, and postpartum resumption in a multi‐state sample, comparing pregnant and nonpregnant people with AUD.

Methods

Using MarketScan combined commercial and Medicaid claims (2016–2019), we identified individuals with AUD who had continuous insurance coverage throughout pregnancy, classifying those with a live birth as pregnant, and compared their MAUD and PSY patterns to nonpregnant peers matched by age, insurance type, and calendar time. All individuals had ≥1 claim for: (a) AUD diagnosis and (b) MAUD or PSY in the year preceding the study. Outcomes—filled MAUD prescriptions (naltrexone, acamprosate, and disulfiram) and receipt of PSY—were identified via claims. We computed rates of MAUD and PSY receipt, stratifying by five observation windows for pregnant individuals (12‐week preconception; first, second, and third trimesters; 12 weeks postpartum) and nonpregnant peers (by corresponding windows). We assessed time to treatment discontinuation using multivariable Cox regression, adjusting for sociodemographics and comorbidities.

Results

Our sample consisted of 2080 pregnant persons with AUD and 7564 matched nonpregnant AUD peers. During pregnancy, MAUD receipt declined from 12.1% (preconception) to 0.3% (third trimester) among pregnant people and from 13.5% to 8.1% in nonpregnant peers during the equivalent time period ( p < 0.001). Postpartum resumption of MAUD was uncommon in the pregnant cohort (pregnant = 1.9%; nonpregnant = 7.8%, p < 0.001). PSY declined for both the pregnant and nonpregnant cohorts yet remained modestly higher in the nonpregnant cohort (postpartum 10.3% vs. 13.8%, p < 0.001). In adjusted analyses, pregnant people were more likely to discontinue MAUD than nonpregnant peers (HR = 2.11 [1.71–2.60]) yet not more likely to discontinue PSY (HR = 1.01 [0.87–1.17]).

Conclusions

Among pregnant people with preconception AUD receiving treatment, MAUD utilization is low and discontinuation is widespread, persisting postpartum.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Postpartum PeriodAlcoholismPregnancy ComplicationsWithholding TreatmentHumansFemalePregnancyUnited StatesAdultYoung AdultNaltrexoneAcamprosateAlcohol DeterrentsDisulfiram

Stichwörter der Autor:innen

acamprosateadministrative claimsalcohol use disorderdisulfiraminsurancenaltrexonepregnancy

Substanzen

NaltrexoneAcamprosateAlcohol DeterrentsDisulfiram

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology and the VCU Institute for Drug and Alcohol Studies, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.
  • Department of Family and Community Medicine, Saint Louis University School of Medicine, St. Louis, Missouri, USA.
  • Department of Psychiatry, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
  • Institute for Informatics, Data Science and Biostatistics, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Friends Research Institute, Baltimore, Maryland, USA.
  • Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.

ORCID-Profile: Caitlin E Martin, Kevin Y Xu

Förderung

  • NIDA NIH HHS
  • NIH HHS
  • Saint Louis University
  • Washington University in St. Louis
  • NIMH NIH HHS
  • NCATS NIH HHS
  • National Institutes of Health

Zitieren

APA

Martin, C. E., Bello, J. K., Galati, B. M., Buss, J. L., Terplan, M., Jones, H. E., Mitchell, K. T., Martins, S. S., Grucza, R. A., Suarez, E. A., & Xu, K. Y. (2025). Discontinuation of treatment for alcohol use disorder during pregnancy and postpartum in the United States. Alcohol, Clinical and Experimental Research, 49(9), 1972-1982. https://doi.org/10.1111/acer.70117

Vancouver

Martin CE, Bello JK, Galati BM, Buss JL, Terplan M, Jones HE, et al. Discontinuation of treatment for alcohol use disorder during pregnancy and postpartum in the United States. Alcohol, Clinical and Experimental Research. 2025;49(9):1972-1982. doi:10.1111/acer.70117

BibTeX
@article{Martin2025,
  author = {Martin, Caitlin E and Bello, Jennifer K and Galati, Bridget M and Buss, Joanna L and Terplan, Mishka and Jones, Hendrée E and Mitchell, Kathleen T and Martins, Silvia S and Grucza, Richard A and Suarez, Elizabeth A and Xu, Kevin Y},
  title = {Discontinuation of treatment for alcohol use disorder during pregnancy and postpartum in the United States},
  journal = {Alcohol, Clinical and Experimental Research},
  year = {2025},
  volume = {49},
  number = {9},
  pages = {1972--1982},
  doi = {10.1111/acer.70117}
}
Kostenlos starten →